NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) CFO Patrick Williams purchased 11,891 shares of NeuroPace stock in a transaction dated Tuesday, November 17th. The shares were bought at an average price of $8.34 per share, with a total value of $99,170.94. Following the completion of the transaction, the chief financial officer owned 79,399 shares in the company, valued at approximately $662,187.66. This trade represents a 17.61% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
NeuroPace Price Performance
Shares of NPCE traded up $0.23 on Tuesday, reaching $8.20. The stock had a trading volume of 684,069 shares, compared to its average volume of 219,143. The firm has a market capitalization of $281.42 million, a PE ratio of -14.64 and a beta of 1.98. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. The firm has a 50-day moving average of $13.07 and a 200 day moving average of $14.71. NeuroPace, Inc. has a twelve month low of $5.46 and a twelve month high of $19.60.
More NeuroPace News
Investors following NPCE have been watching these news items:
- Positive Sentiment: Brokerages’ average target price is reported at $20.50, above the current share price. Brokerage average target price article
- Neutral Sentiment: NeuroPace’s discounted valuation and the growth potential of its RNS system are cited as opportunities, but the article says weak implant activity, execution challenges and regulatory risks complicate the outlook. Zacks analysis of growth potential and execution risk
- Negative Sentiment: Coverage also points to a third-quarter miss and lower analyst fair-value estimates, reinforcing concerns about near-term performance. Fair-value estimates after third-quarter miss
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the company. KeyCorp dropped their price target on NeuroPace from $18.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday. Weiss Ratings downgraded NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Raymond James Financial set a $21.00 target price on NeuroPace in a research note on Tuesday, September 15th. Wolfe Research cut NeuroPace from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Wall Street Zen cut NeuroPace from a “hold” rating to a “sell” rating in a report on Saturday. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $13.11.
Read Our Latest Research Report on NeuroPace
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in NPCE. Soleus Capital Management L.P. lifted its holdings in NeuroPace by 10.5% in the 3rd quarter. Soleus Capital Management L.P. now owns 3,218,000 shares of the company’s stock valued at $44,280,000 after purchasing an additional 306,878 shares in the last quarter. First Light Asset Management LLC boosted its stake in shares of NeuroPace by 16.3% during the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after purchasing an additional 401,201 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of NeuroPace during the second quarter worth about $39,369,000. Deutsche Bank AG purchased a new stake in shares of NeuroPace during the second quarter worth about $14,919,000. Finally, Algert Global LLC raised its position in shares of NeuroPace by 2.9% in the second quarter. Algert Global LLC now owns 184,774 shares of the company’s stock valued at $2,936,000 after buying an additional 5,218 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Featured Articles
- Five stocks we like better than NeuroPace
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
